Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
February 3, 2015 4:05 PM ESTRevenues of $184.4 Million Adjusted Diluted EPS of $0.40, and Diluted EPS of $0.32 myRisk Hereditary Cancer Revenues of $85.1 Million BRACAnalysis CDx Approved by the FDA Tumor BRACAnalysis CDx Granted European CE Marking Approval Company Revises Fiscal Year 2015 Financial Guidance; Provides Fiscal 3Q15 Financial Guidance
SALT LAKE CITY, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN) today announced financial results for its fiscal second-quarter and six months ended December 31, 2014, provided an update on recent business highlights,... More
